微芯生物：与Nizhpharm签署许可及分销协议

Core Viewpoint - Microchip Biotech (688321.SH) has signed a licensing and distribution agreement with Nizhny Novgorod Chemical Pharmaceutical Plant (Nizhpharm) for the product Sidabenamine, granting Nizhpharm exclusive rights for research, registration, and commercialization in several countries [1][2] Group 1 - The agreement allows Nizhpharm to have exclusive rights for Sidabenamine in Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Russia, Tajikistan, Uzbekistan, Georgia, and Turkmenistan, as well as any future countries with capitals in these regions [1] - Nizhpharm will be responsible for the product's research, market registration, secondary packaging, transportation, and commercialization in the authorized regions [2] - The company will receive an upfront payment of 10 million RMB and additional milestone payments totaling 10 million RMB for local registration upon the agreement's effectiveness [2] Group 2 - Nizhpharm will purchase the product from the company at an agreed price for commercialization in the authorized regions, with the company receiving a high double-digit percentage of sales based on net sales in those areas [2] - The agreement will last for 10 years from the date the licensed product first receives market approval in the authorized region, unless terminated early as per contract terms [2]